TG Therapeutics down 11% after Q2 earnings miss
TG Therapeutics reported Q2 earnings per share of $0.05, missing expectations.
The company’s Q2 EPS compares to $0.17 in the year-ago period.
Revenue increased 70% year-over-year, but this was not enough to offset the earnings miss.